Using the technology developed by researchers at the University of Illinois, Shield T3 provides a comprehensive solution to curb and control the spread of COVID-19. Shield T3’s test functions at a cost, speed and accuracy that outperforms other currently available tests. In addition, the program offers a mobile app that delivers rapid notification of test results and keeps constituents informed of testing requirements. Shield T3 is named after the program’s “Target, Test, Tell” strategy to identify trends earlier, allowing organizations to take rapid action and minimize outbreaks where and when they occur.
The program uses a “Target, Test, Tell” strategy to identify trends earlier, allowing organizations to take rapid action and minimize outbreaks where and when they occur. Our saliva test is easier to administer, taking less than 3 minutes with results delivered to a customer’s phone in 6-12 hours.
The Shield T3 service model is based on a mobile testing lab. We offer two different variations. One, we build the lab, open the lab and run the lab. The other is a services agreement. You can think of it as a consulting agreement. Our team helps larger institutions set up their own lab and testing protocols, based on our intellectual property. In other words, we give them a roadmap on how to do this on their own.
For larger companies and universities, it’s a game-changer. It offers fewer supply chain challenges, allowing for targeted local operation and control. Further, we test for three genes present in COVID-19 (vs. one gene for some other tests), with a specificity of 99.8-99.9% and very, very few false positives.
What else would we like to share about the lab and contributions from the University of Illinois to fight the COVID-19 pandemic?
“Once you know where the virus is, you can deal with it. If you don’t know where it is, it’s very tricky. It will develop.” – University of Illinois System President Tim Killeen